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Human African trypanosomiasis, also known as sleeping sick ness, is a vector borne parasitic disease and also a serious health threat to a large number of people living in sub Saharan Africa where health systems are least effective, or even non existent. 1-3 Trypanosoma brucei gambiense (T. b. gambiense) and Trypanosoma brucei rhodesiense (T. b. rhodesiense) are the etiological parasites of sleeping sickness in humans. In West and Central Africa, T. b. gambiense is the major parasite to cause the disease, while in sub Saharan Africa, T. b. rhodesiense predominates. These subspe cies of trypanosome are responsible for the West and East African forms of the disease, respectively. 2 The main difference between the two infections is the rate of progression from the blood/lym phatic stage to the cerebral stage. T. b. gambiense infection is chronic because it takes months for the disease to progress. By con trast, the infection of T. b. rhodesiense is more acute, and could reach the cerebral stage in one to three weeks. For, T. b. gambiense, humans are the main hosts. However, wild and domestic animals, especially cattle, are the major reservoirs for T. b. rhodesiense. 1 A third closely related subspecies, Trypanosoma brucei brucei (T. b. brucei), is less infectious to humans, but is responsible for many cases of nagana in cattle. It significantly limits the agricultural development in Africa. 4,5 As T. b. brucei shares many features with T. b. gambiense and T. b. rhodesiense (such as antigenic variation), it is often used as a model for human infections in laboratory and animal studies.
The current chemotherapy of the human trypanosomiasis relies on only five drugs including Suramin, Pentamidine, Melarsoprol, Eflornithine and Nifurtimox Eflornithine combination. 6 The main drawbacks of these drugs are: (1) high toxicity to the hosts, which is mainly due to their poor selectivity to the parasite cells than the mammalian cells; (2) these agents have to be administered via intramuscular or intravenous injections; (3) they have very narrow anti trypanosomiasis spectrum; and (4) treatment using these drugs needs the high cost of hospitalization. Overall, these drugs are not successful in the treatment of the disease, and there is a general lack of effective, inexpensive chemotherapeutic agents for the treatment of human African trypanosomiasis. Clearly, im proved chemotherapeutics with better selectivity to the trypano somes are needed to effectively battle this disease. 5, 7, 8 Tubulin containing structures are important for many impor tant cellular functions, including chromosome segregation during cell division, intracellular transport, development and mainte nance of cell shape, cell motility, and distribution of molecules on cell membranes. 9 Tubulin is a very attractive target in anti cancer drug discovery field, and several successful tubulin binders are the first line chemotherapeutic agents in clinic. 10 Tubulin also plays an essential role during trypanosome cell division. The fast population doubling rate of trypanosomes makes them highly dependent on tubulin polymerization/depolymerization. 11 More importantly, tubulin is very critical for the trypanosome locomo tion, which is an essential function for trypanosomes to survive.
The T. brucei cell body is roughly cylindrical in shape with tapered anterior and posterior ends. A single flagellum emerges from the basal body near the posterior end of the cell. Within the flagellum is a canonical '9+2' microtubule axoneme that drives flagellar movement. 12 Tubulin inhibitors not only block the T. brucei cell division but will also affect the locomotion function of flagellum and lead to cell death. 13 The flagellar pocket is known to be an important structure in the uptake and internalization of molecules for trypanosomes. 14 Such uptake could enhance the binding of the tubulin inhibitors to intracellular tubulin, particularly in the fla gella pocket. Therefore, tubulin inhibitors could be effective agents to suppress flagellar locomotion function. 13 These factors indicate that there are potential advantages of tubulin inhibitors for the treatment of trypanosomiasis. In addition, identification of binding pockets uniquely located on T. brucei tubulin would allow develop ment of selective tubulin inhibitors, which could dramatically re duce the toxic effects of the anti parasite drugs to the host cells.
Tubulin is a highly conserved protein. Examination of tubulin sequences from mammalian cells and yeast cells reveals 70 90% identity. However, differences in susceptibility to antimitotic agents are known to exist between tubulins from different organ isms, suggesting that differences of tubulin structures exist among different species. 15 For example, the antifungal compound methyl N (benzimidazol 2 yl) carbamate shows high selectivity to yeast tubulin. It has been reported that the compound is at least 300 fold more potent as an inhibitor of yeast tubulin than that of bovine brain tubulin. 16 In addition, oxfendazole and thiabendazole com pounds are also more effective to inhibit nematode tubulin poly merization than mammalian tubulin. 17 The results from these investigations reveal that there are differences in tubulin drug sus ceptibility for different organisms. Based on the differences of tubulin in T. brucei and mammalian cells, it is highly expected that selective tubulin inhibitors could be developed. Some microtubule disrupting herbicides such as phosphoric thioamide herbicide amiprophos methyl (APM) and dinitroaniline herbicides exhibit activity against protozoan parasites by aiming tubulin as the molecule target. 15, [17] [18] [19] [20] Research has been done to optimize these compounds to generate more potent and selective tubulin inhibi tors for T. brucei. 15 Werbovetz's group successfully developed sev eral drug candidates showing promising in vitro anti parasite activity and selectivity. However, these compounds did not show good in vivo potency due to the poor stability. 21 However, these investigations demonstrated the feasibility to generate selective tubulin inhibitors as anti trypanosomal agents.
To search for selective tubulin inhibitors as better therapeutic agents to treat sleeping sickness, we firstly examined the inhibitory activity of several tubulin inhibitors that are current clinical drugs or in clinical trials for cancer treatment 10,22 on T. brucei (T. b. brucei was used as the representative strain) with 3 (4,5 dimethylthiazol 2 yl) 5 (3 carboxymethoxyphenyl) 2 (4 sulfophenyl) 2H tetrazo lium (MTS) assay, 23 then on mammalian cell growth (SKBR 3 breast cancer cell line as a model) with MTT assay. 24 Among the few tested drugs, paclitaxel showed very similar activity on both T. brucei and SKBR 3 breast cancer cells (Table 1 ), suggesting that tubulin binding domain of paclitaxel is very similar in the two organisms. However, vinblastine and the colchicine domain binders including colchicine, indibulin, 25 nocodazole and ABT751 22 exhibited strong inhibition to mammalian cells but very weak inhibitory effect on T. brucei growth, which is consistent to other studies focusing on tubulin inhibitors with T. brucei. 26, 27 These results suggest that sig nificant differences exist in the colchicine binding domain between mammalian and T. brucei tubulins.
Due to the very different biological activities of the well defined tubulin inhibitors on mammalian and T. brucei cells, we compared the tubulin amino acid sequence of the two organisms (Table 2) . Bovine tubulin was listed as a representative of mammalian tubu lin. T. brucei tubulin showed an 85% identity to bovine a tubulin and 86% identity to bovine b tubulin when analyzed with SWISS MODEL repository. 28, 29 It is hard to estimate whether the binding sites of tubulin inhibitors are very different between mammalian and T. brucei cells just based on the protein sequence comparison. However, the difference of certain key amino acids of tubulin is very likely to affect the tubulin inhibitor's binding affinity. It has been reported that Leucine 316 of b Tubulin (Table 2 , L316 is marked in blue) is critical for colchicine activity against bovine tubulin polymerization. [30] [31] [32] In T. brucei b tubulin, residue 316 is changed to Valine, which is expected to greatly decrease the col chicine binding and presumably explains the weak inhibitory activity of colchicine on the growth of T. brucei cells (Table 1) .
To further illustrate the difference of the colchicine binding do main of bovine and T. brucei tubulin, a predicated structure of T. brucei tubulin was generated based on the crystal structure of bo vine tubulin (PDB1SA0) 30 using SWISS MODEL Repository program (Fig. 1) . 28, 29 The model shows great similarity between T. brucei and bovine tubulin, since the protein sequence identity is 85%. How ever, the colchicine binding domain shows clear difference be tween the two types of tubulins. Several b sheets of the bovine and the T. brucei tubulin (Fig. 1B, circled area) in the colchicine binding domain do not overlap well. These b sheets form the bind ing pocket for colchicine, and are critical for ligand binding. Other colchicine domain binder including nocodazole, indibulin, and ABT751 also rely on these b sheets to bind to tubulin. 30, 33 The dif ference between the effects of these well defined tubulin inhibi tors on T. brucei and mammalian cells (Table 1) is also consistent with the predicated structure difference between the two tubulin homologous. This significant docking site difference provides a good foundation for the development of selective colchicine domain binders for the treatment of sleeping sickness.
We previously developed a class of sulfonamide tubulin inhibi tors (Table 3) as anti cancer agents. 24, 34 These inhibitors were identified to be colchicine domain binders and some of them exhibited very potent cell cycle arrest and apoptosis inducing activity in mammalian cells. 24 Due to the structural diversity of their benzamide moiety, we hypothesized that some of the analogs might selectively inhibit T. brucei growth, since mammalian and T. brucei tubulin exhibit differences on colchicine binding domain, particularly at the benzamide moiety binding pocket ( Figs. 1 and  2) . More specifically, the benzamide moiety of the tubulin inhibi tors interacts with the b sheets of the colchicine binding domain as indicated with blue arrows in Figure 2 . 34 The differences of these b sheets in T. brucei and mammalian cells will form different bind ing pockets, and highly likely cause different interactions with dif ferent benzamide moieties, which will lead to selectivity.
The compounds were tested with T. brucei cell growth assay, and the IC 50 s are listed in Table 3 . The activities against SKBR 3 breast cancer cells from previous studies 24 are listed in the table for comparison. Several compounds, including 3, 17, 26, 38, and 43, exhibited very specific inhibitory effect on T. brucei growth, with selectivity index (IC 50 inhibiting human cancer cell growth/ IC 50 inhibiting T. brucei growth) being five or more. Particularly, 
